File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinicopathological features of hepatitis C virus antibody negative fatal chronic hepatitis C after renal transplantation

TitleClinicopathological features of hepatitis C virus antibody negative fatal chronic hepatitis C after renal transplantation
Authors
Issue Date1995
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/NEF
Citation
Nephron, 1995, v. 71 n. 2, p. 213-217 How to Cite?
AbstractClinical course and serial liver histology of a patient who developed fatal chronic active hepatitis C after renal transplantation are presented. This patient developed persistently deranged liver biochemistry 3 months after transplantation, despite normal liver enzyme values during the preceding 3 years on hemodialysis. In addition to increased parenchymal enzyme concentrations, the levels of ductal enzymes were also markedly elevated, with peak levels of alanine aminotransferase and γ-glutamyl transpeptidase 7 and 100 times, respectively, the normal upper limit. The patient was persistently seronegative for hepatitis C virus (HCV) antibodies, but positive for HCV RNA. Treatment with α-interferon for 6 months, initiated after the development of early cirrhosis, resulted in no improvement, and the patient died from liver failure 36 months after renal transplantation. Serial liver histology, examined four times from 11 months to 36 months after transplantation, showed progressive deterioration from chronic active hepatitis to cirrhosis. This patient illustrates the uncommon complication of rapidly progressive and ultimately fatal liver disease due to HCV infection after renal transplantation. Early recognition with anti-HCV and HCV RNA assays as well as histologic assessment are crucial for the identification of patients with a poor prognosis who might benefit from therapeutic intervention before irreversible liver damage.
Persistent Identifierhttp://hdl.handle.net/10722/162100
ISSN
2004 Impact Factor: 1.462
2006 SCImago Journal Rankings: 0.715
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorLok, ASFen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorCheng, IKPen_US
dc.date.accessioned2012-09-05T05:17:20Z-
dc.date.available2012-09-05T05:17:20Z-
dc.date.issued1995en_US
dc.identifier.citationNephron, 1995, v. 71 n. 2, p. 213-217en_US
dc.identifier.issn0028-2766en_US
dc.identifier.urihttp://hdl.handle.net/10722/162100-
dc.description.abstractClinical course and serial liver histology of a patient who developed fatal chronic active hepatitis C after renal transplantation are presented. This patient developed persistently deranged liver biochemistry 3 months after transplantation, despite normal liver enzyme values during the preceding 3 years on hemodialysis. In addition to increased parenchymal enzyme concentrations, the levels of ductal enzymes were also markedly elevated, with peak levels of alanine aminotransferase and γ-glutamyl transpeptidase 7 and 100 times, respectively, the normal upper limit. The patient was persistently seronegative for hepatitis C virus (HCV) antibodies, but positive for HCV RNA. Treatment with α-interferon for 6 months, initiated after the development of early cirrhosis, resulted in no improvement, and the patient died from liver failure 36 months after renal transplantation. Serial liver histology, examined four times from 11 months to 36 months after transplantation, showed progressive deterioration from chronic active hepatitis to cirrhosis. This patient illustrates the uncommon complication of rapidly progressive and ultimately fatal liver disease due to HCV infection after renal transplantation. Early recognition with anti-HCV and HCV RNA assays as well as histologic assessment are crucial for the identification of patients with a poor prognosis who might benefit from therapeutic intervention before irreversible liver damage.en_US
dc.languageengen_US
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/NEFen_US
dc.relation.ispartofNephronen_US
dc.subject.meshAdulten_US
dc.subject.meshAlanine Transaminase - Metabolismen_US
dc.subject.meshAlkaline Phosphatase - Metabolismen_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshHepacivirus - Immunologyen_US
dc.subject.meshHepatitis Antibodies - Blooden_US
dc.subject.meshHepatitis C - Enzymology - Immunology - Surgeryen_US
dc.subject.meshHumansen_US
dc.subject.meshKidney Transplantationen_US
dc.subject.meshLiver Diseases - Enzymology - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshGamma-Glutamyltransferase - Metabolismen_US
dc.titleClinicopathological features of hepatitis C virus antibody negative fatal chronic hepatitis C after renal transplantationen_US
dc.typeArticleen_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1159/000188715-
dc.identifier.pmid8569957-
dc.identifier.scopuseid_2-s2.0-0029113423en_US
dc.identifier.hkuros11285-
dc.identifier.volume71en_US
dc.identifier.issue2en_US
dc.identifier.spage213en_US
dc.identifier.epage217en_US
dc.identifier.isiWOS:A1995RY03100018-
dc.publisher.placeSwitzerlanden_US
dc.identifier.scopusauthoridChan, TM=7402687700en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridCheng, IKP=7102537483en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats